Shares of Autolus Therapeutics PLC (NASDAQ: AUTL) surged over 5% in pre-market trading on Monday, following the company's announcement that its lead product, AUCATZYL® (obecabtagene autoleucel), has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of relapsed/refractory (r/r) adult B-cell acute lymphoblastic leukemia (B-ALL).
The FDA approval of AUCATZYL®, a CD19-targeted chimeric antigen receptor (CAR) T-cell therapy, marks a significant milestone for Autolus as it becomes the company's first commercial product. The approval triggers a $30 million milestone payment to Autolus from its collaborator Blackstone, further strengthening the company's financial position.
In addition to the FDA approval, Autolus reported positive third-quarter 2024 financial results, with cash and cash equivalents totaling $657 million as of September 30, 2024. This strong cash position is expected to support the commercialization of AUCATZYL® and the advancement of the company's pipeline programs, including AUTO8 for multiple myeloma, AUTO6NG for neuroblastoma, and AUTO1/22 for pediatric acute lymphoblastic leukemia.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.